Trial site
Hopital Larrey
Toulouse, 31059, FranceNot linked to an institution yet
- 16running trials
- 14closed trials
The trials here
What the 30 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 23 trials
- Phase 2/32 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Completed13 trials
- Recruiting8 trials
- Active, not recruiting5 trials
- Not yet recruiting2 trials
- Enrolling by invitation1 trial
- Terminated1 trial
- Lead sponsor
- Eli Lilly and Company2 trials
- Groupe Francais De Pneumo-Cancerologie2 trials
- Hoffmann-La Roche2 trials
- Institut Claudius Regaud2 trials
- Pfizer2 trials
- and 20 more
Running trials
Not yet recruiting
Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty
NCT07644377· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Contact: Elise NOEL SAVINA, MD
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Recruiting
Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
NCT07243132· GFPC Investigation· Source
Contact: Laurence BIGAY-GAME
Recruiting
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
NCT06701513· Bristol-Myers Squibb· Source
Contact: MAELLA SEVERINO FREIRE, Site 037
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245· Phase 3· OSE Immunotherapeutics· Source
Contact: Caroline Chevalier, MSc, MPH
Active, not recruiting
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109· Pfizer· Source
Recruiting
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
NCT05689151· Pfizer· Source
Active, not recruiting
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565· Phase 2/3· Biogen· Source
Enrolling by invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693· Phase 3· United Therapeutics· Source
Active, not recruiting
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
NCT05382156· RECORDATI GROUP· Source
Recruiting
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NCT05122806· Groupe Francais De Pneumo-Cancerologie· Source
Contact: Laurence BIGAY-GAME
Recruiting
Deciphering Mechanisms Underlying Cancer Immunogenicity
NCT03958240· Institut Claudius Regaud· Source
Contact: Julien MAZIERES
Active, not recruiting
Evaluation of the Safety and Efficacy of TLD in Patients with COPD
NCT03639051· Nuvaira, Inc.· Source
Recruiting
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer
2024-512173-27-00· Phase 3· Unicancer· Source
Recruiting
FARD (RaDiCo Cohort) (RaDiCo-FARD)
NCT05954416· Institut National de la Santé Et de la Recherche Médicale, France· Source
Contact: Juliette MAZEREEUW-HAUTIER
Active, not recruiting
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02779751· Phase 1· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis
NCT06147778· Ad scientiam· Source
Completed
Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients
NCT05988970· Institut Claudius Regaud· Source
Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source
Completed
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
NCT05322096· Phase 2· Gedeon Richter Plc.· Source
Completed
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
NCT05308966· Groupe Francais De Pneumo-Cancerologie· Source
Completed
Zephyr Etude Post-Inscription (French Registry)
NCT04517916· Pulmonx Corporation· Source
Completed
Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation
NCT04233021· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Completed
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
NCT04392154· Phase 3· Eli Lilly and Company· Source
Completed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502· Phase 3· Takeda· Source
Completed
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
NCT04010253· Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche· Source
Completed
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
NCT03782207· Hoffmann-La Roche· Source
Completed
Quality of Sleep of Patients With Predominant Central Sleep Apnea Syndrome(SAS) Whose EF > 45% Treated by ASV
NCT02835638· Société Française de Recherche et de Médecine du Sommeil· Source
Completed
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT03037385· Phase 1/2· Hoffmann-La Roche· Source
Completed
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
NCT02784171· Phase 2/3· Canadian Cancer Trials Group· Source
Report an error